PROSTA SPÓŁKA AKCYJNA
H+H LABS
H+H LABS Prosta Spółka Akcyjna
PROSTA SPÓŁKA AKCYJNA
H+H LABS Prosta Spółka Akcyjna
H+H LABS Prosta Spółka Akcyjna (KRS 0000962001, NIP 5783153218) is a Polish company, headquartered in Elbląg, Warmińsko-Mazurskie voivodeship. H+H LABS operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since March 23, 2022. H+H LABS's most recently reported net revenue was 0 PLN for 2023.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Credibility rating
44.7 / 100
Average credibility
Insolvency risk
Low
Elevated threat
Closure risk
41
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/4 yrs
Board changes
2
2/4 yrs
PKD changes
0
0/4 yrs
Name changes
0
0/4 yrs
Data from 4 years of registry activity.
Payment reliability score from 2022–2023
Current: D (45/100)
Trend: deteriorating (-11.4 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Standard limit from 2022–2023
Current: 4.7 K PLN
Safe: 1.4 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Founded
March 23, 2022
4 years in operation
Legal form
PROSTA SPÓŁKA AKCYJNA
Registry: RejP
Headquarters
ELBLĄG
WARMIŃSKO-MAZURSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
N/A
Shareholders
N/A
Board
1 person
Sup. board: 3 · Proxies: 1
Filed years
2 years
2022–2023 · profitable: 0/2
Registry entries
16
latest: June 3, 2026
Risk signals
Revenue
0 PLN
2023
Net profit
-57.0 K PLN
2023
Assets
53.2 K PLN
2023
Equity
27.8 K PLN
2023
EBITDA
-56.3 K PLN
2023
Valuation
16.2 K PLN
Low confidence
Low confidence
Rate business credibility - H+H LABS.
No ratings
News
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
H+H LABS's board has 1 member.
Latest reporting year
2024
Available years
3
Filing entries
0
16 historical registry entries for H+H LABS
Filing document
Filing documents submitted (3 documents)
Change in Section 1 (basic data)
OL.VIII NS-REJ.KRS/6501/22/340/ADE
Filing document
Board change
OL.VIII NS-REJ.KRS/7691/26/413
Competing companies or those operating in the same market segment as H+H LABS (in Elbląg, industry: Research and development).
OLSZTYN· Research and development
Revenue 2024: 40.8 M PLN
ELBLĄG· Research and development
Revenue 2024: 37.2 M PLN
PISZ· Research and development
Revenue 2024: 5.8 M PLN
OLSZTYN· Research and development
Revenue 2024: 2.0 M PLN
OLSZTYN· Research and development
Revenue 2024: 846.4 K PLN
MORĄG· Research and development
Revenue 2022: 691.9 K PLN
